Efficacy of soluble fibre, antispasmodic drugs, and gut–brain neuromodulators in irritable bowel syndrome: a systematic review and network meta-analysis

Published on Feb 1, 2020in The Lancet Gastroenterology & Hepatology14.789
· DOI :10.1016/S2468-1253(19)30324-3
Christopher J Black13
Estimated H-index: 13
(University of Leeds),
Yuhong Yuan35
Estimated H-index: 35
(McMaster University)
+ 4 AuthorsAlexander C. Ford86
Estimated H-index: 86
(University of Leeds)
Sources
Abstract
Summary Background Although novel therapies for irritable bowel syndrome (IBS) continue to be developed, many doctors rely on more established, traditional therapies as first-line or second-line treatment options. These therapies include soluble fibre (eg, ispaghula husk), antispasmodic drugs, peppermint oil, and gut–brain neuromodulators (including tricyclic antidepressants, selective serotonin reuptake inhibitors, or α-2-δ calcium channel subunit ligands). However, the relative efficacy of traditional treatments in patients with IBS is unclear because there have been few head-to-head randomised controlled trials (RCTs). We aimed to compare and rank the efficacy of traditional therapies in patients with IBS to help inform clinical decisions. Methods For this systematic review and network meta-analysis, we searched MEDLINE, Embase, Embase Classic, and the Cochrane Central Register of Controlled Trials from inception to week 2 of August 2019; ClinicalTrials.gov for unpublished trials or supplementary data published up to Aug 18, 2019; and gastroenterology conference proceedings for study abstracts published between 2001 and Aug 18, 2019. We included RCTs that compared any of these treatments with each other (head-to-head trials) or with placebo, in which the efficacy of soluble fibre, antispasmodic drugs, peppermint oil, or gut–brain neuromodulators was assessed in adults (aged at least 18 years) with IBS of any subtype after 4–12 weeks of treatment. Only RCTs reporting a dichotomous assessment of overall response to therapy, in terms of either improvement in global IBS symptoms or improvement in abdominal pain, were included. The efficacy and safety of all treatments were reported as a pooled relative risk (RR) with 95% CIs to summarise the effect of each comparison tested, and treatments were ranked according to their P-score. Findings Our search identified 5863 references, of which 81 were screened for eligibility. 51 RCTs with data from 4644 patients were eligible for inclusion in our analysis, but only 13 of these trials were at low risk of bias. Based on an endpoint of failure to achieve improvement in global IBS symptoms at 4–12 weeks, peppermint oil capsules were ranked first for efficacy (RR 0·63, 95% CI 0·48–0·83, P-score 0·84) and tricyclic antidepressants were ranked second (0·66, 0·53–0·83, P-score 0·77). For failure to achieve an improvement in global IBS symptoms at 4–12 weeks, there were no significant differences between active treatments after direct or indirect comparisons. For failure to achieve improvement in abdominal pain at 4–12 weeks, tricyclic antidepressants were ranked first for efficacy (0·53, 0·34–0·83, P-score 0·87); however, this result was based on data from only four RCTs involving 92 patients. For failure to achieve an improvement in abdominal pain, none of the active treatments showed superior efficacy upon indirect comparison. Tricyclic antidepressants were more likely than placebo to lead to adverse events (1·59, 1·26–2·06, P-score 0·16). Interpretation In this network meta-analysis of RCTs of soluble fibre, antispasmodic drugs, peppermint oil, and gut–brain neuromodulators for IBS, few of which were judged as being at a low risk of bias, peppermint oil was ranked first for efficacy when global symptoms were used as the outcome measure, and tricyclic antidepressants were ranked first for efficacy when abdominal pain was used as the outcome measure. However, because of the lack of methodological rigour of some RCTs analysed in our study, there is likely to be considerable uncertainty around these findings. In addition, because treatment duration in most included trials was 4–12 weeks, the long-term relative efficacy of these treatments is unknown. Funding None.
📖 Papers frequently viewed together
1 Citations
201919.82Gut
81 Citations
References78
Newest
#1Christopher J Black (University of Leeds)H-Index: 13
#2Nicholas E Burr (University of Leeds)H-Index: 14
Last. Alexander C. Ford (University of Leeds)H-Index: 86
view all 3 authors...
: Irritable bowel syndrome (IBS) is a chronic functional bowel disorder affecting 1 in 10 people and associated with poor psychological health, reduced quality of life, and increased health care expenditure.1 The etiology is complex and incompletely understood.2 Approximately one-third of patients have IBS with constipation (IBS-C),1 for which there are licensed therapies available in the United States. We summarized comparative efficacy of these in a recent network meta-analysis of randomized c...
26 CitationsSource
#1Christopher J Black (University of Leeds)H-Index: 13
#2Nicholas E Burr (University of Leeds)H-Index: 14
Last. Alexander C. Ford (University of Leeds)H-Index: 86
view all 8 authors...
Objective Over half of patients with IBS have either diarrhoea (IBS-D) or a mixed stool pattern (IBS-M). The relative efficacy of licenced pharmacological therapies is unclear in the absence of head-to-head trials. We conducted a network meta-analysis to resolve this uncertainty. Design We searched MEDLINE, Embase, Embase Classic, the Cochrane central register of controlled trials, and Clinicaltrials.gov through January 2019 to identify randomised controlled trials (RCTs) assessing the efficacy ...
49 CitationsSource
#1Julian P T Higgins (University of Cambridge)H-Index: 135
#2Sally Green (Cochrane Collaboration)H-Index: 66
The Cochrane Handbook for Systematic Reviews of Interventions is the official document that describes in detail the process of preparing and maintaining Cochrane systematic reviews on the effects of healthcare interventions.
10.8k Citations
#1Zsa Zsa R. M. Weerts (UM: Maastricht University)H-Index: 5
#2Ad A. M. Masclee (UM: Maastricht University)H-Index: 1
Last. Daniel Keszthelyi (UM: Maastricht University)H-Index: 28
view all 16 authors...
Abstract Background & Aims Peppermint oil is frequently used to treat irritable bowel syndrome (IBS), despite a lack of evidence for efficacy from high-quality controlled trials. We studied the efficacy and safety of small intestinal-release peppermint oil in patients with IBS and explored the effects of targeted ileocolonic-release peppermint oil. Methods We performed a double-blind trial of 190 patients with IBS (according to Rome IV criteria) at 4 hospitals in the Netherlands, from August 201...
29 CitationsSource
OBJECTIVE: To provide an overall estimate of the direct, indirect and total costs of irritable bowel syndrome (IBS) for the adult population of the European countries with universal healthcare coverage. MATERIALS AND METHODS: We searched MedLine and Scopus databases (up to September 2018) to identify the European studies that evaluated the economic impact of IBS. Mean annual direct, indirect and total per-capita IBS costs were estimated using random-effect single-group meta-analyses of continuou...
13 CitationsSource
#1Yuri A. Saito (Mayo Clinic)H-Index: 28
#2Ann E. Almazar (Mayo Clinic)H-Index: 6
Last. Nicholas J. Talley (University of Newcastle)H-Index: 183
view all 8 authors...
BACKGROUND: Pregabalin is a calcium channel α2δ ligand that modifies visceral hypersensitivity in IBS patients. Clinical data for pregabalin in IBS are lacking. AIM: To test the efficacy of pregabalin on gastrointestinal symptoms in IBS patients. METHODS: A double-blind, placebo-controlled trial was performed. Adults meeting IBS Rome III criteria with ≥3 pain attacks per month were randomised to pregabalin 225 mg vs placebo twice daily for 12 weeks. Questionnaires were completed weekly. The prim...
13 CitationsSource
#1Christopher J Black (University of Leeds)H-Index: 13
#2Nicholas E Burr (University of Leeds)H-Index: 14
Last. Alexander C. Ford (University of Leeds)H-Index: 86
view all 6 authors...
Background & Aims Several secretagogues have been approved for the treatment of irritable bowel syndrome with constipation (IBS-C). However, their relative efficacy is unclear because there have been no head-to-head randomized controlled trials. We conducted a network meta-analysis to compare their efficacies in patients with IBS-C. Methods We searched MEDLINE, EMBASE, EMBASE Classic, and the Cochrane Central Register of Controlled Trials through June 2018 to identify randomized controlled trial...
68 CitationsSource
#1Åsa Frändemark (University of Gothenburg)H-Index: 2
#2Hans Törnblom (University of Gothenburg)H-Index: 33
Last. Magnus Simrén (University of Gothenburg)H-Index: 78
view all 4 authors...
Patients with irritable bowel syndrome (IBS) are more likely to be both absent from and impaired at work compared to non-IBS patients. We investigated the impact of IBS on work productivity and activity impairment and the relationship to disease specific and general health measures. In total, 525 patients with IBS completed questionnaires assessing work productivity and activity impairment, IBS symptom severity, IBS-related quality of life and GI-specific anxiety. In addition, 155 of the patient...
36 CitationsSource
#1Alexander C. Ford (University of Leeds)H-Index: 86
#2Paul Moayyedi (McMaster University)H-Index: 115
Last. Eamonn Martin Quigley (Cornell University)H-Index: 120
view all 7 authors...
INTRODUCTIONIrritable bowel syndrome (IBS) is the most prevalent of the functional gastrointestinal disorders (FGIDs). Current estimates are that IBS affects up to 10–12% of adults in North America [1, 2]. Although it can affect all individuals regardless of age, creed, or gender, IBS is more common
131 CitationsSource
#1Johanne L. Agger (Aarhus University Hospital)H-Index: 3
#2Andreas Schröder (Aarhus University Hospital)H-Index: 16
Last. Per Fink (Aarhus University Hospital)H-Index: 55
view all 6 authors...
Summary Background Functional somatic syndromes, including chronic fatigue syndrome or irritable bowel syndrome, often co-exist. Treatment guidelines supported by high quality evidence exist for most functional somatic syndromes, but are lacking for multiple comorbid functional somatic syndromes. We aimed to assess the effect of the tricyclic antidepressant, imipramine, in patients with multiple functional somatic syndromes defined by the criteria for multiorgan bodily distress syndrome, a unify...
27 CitationsSource
Cited By32
Newest
#1Christopher J Black (University of Leeds)H-Index: 13
#2Heidi M Staudacher (Deakin University)H-Index: 20
Last. Alexander C. Ford (University of Leeds)H-Index: 86
view all 3 authors...
Objective null A diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAP) is recommended for irritable bowel syndrome (IBS), if general lifestyle and dietary advice fails. However, although the impact of a low FODMAP diet on individual IBS symptoms has been examined in some randomised controlled trials (RCTs), there has been no recent systematic assessment, and individual trials have studied numerous alternative or control interventions, meaning the best com...
Source
#1Laurie Keefer (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 40
#2Cynthia W. Ko (UW: University of Washington)H-Index: 25
Last. Alexander C. Ford (University of Leeds)H-Index: 86
view all 3 authors...
Description null This expert review summarizes approaches to management of pain in disorders of gut–brain interaction. This review focuses specifically on approaches to pain that persist if first-line therapies aimed at addressing visceral causes of pain are unsuccessful. The roles of a therapeutic patient–provider relationship, nonpharmacologic and pharmacologic therapies, and avoidance of opioids are discussed. null null null Methods null This was not a formal systematic review but was based o...
Source
Irritable bowel syndrome (IBS) is a common disorder of gut-brain interaction which can have a considerable impact on quality of life. Following diagnosis, timely and evidence-based management is vital to the care of patients with IBS, aiming to improve outcomes, and enhance patient satisfaction. Good communication is paramount, and clinicians should provide a clear explanation about the disorder, with a focus on exploring the patient’s own beliefs about IBS, and a discussion of any concerns they...
Source
#1Hans Törnblom (University of Gothenburg)H-Index: 33
#2Douglas A. Drossman (UNC: University of North Carolina at Chapel Hill)H-Index: 103
Psychopharmacologic therapies are beneficial in reducing symptoms when treating irritable bowel syndrome (IBS) and other disorders of gut-brain interaction (DGBI). Noradrenaline, serotonin, and dopamine are neurotransmitters of key importance in psychopharmacology and pain-reduction mechanisms. The first-line (tricyclic antidepressants, serotonin noradrenaline reuptake inhibitors, selective serotonin reuptake inhibitors) and second-line (atypical antipsychotics, delta-ligand agents, low-dose nal...
Source
#1Benjamin Nulsen (UCLA: University of California, Los Angeles)H-Index: 2
#2Wendi LeBrett (UCLA: University of California, Los Angeles)H-Index: 1
Last. Lin Chang (UCLA: University of California, Los Angeles)H-Index: 73
view all 4 authors...
Background null Central neuromodulators are an effective treatment for irritable bowel syndrome (IBS) but may be used less frequently than other therapies. null Aims null To survey gastroenterologists in the United States (US) about their use of neuromodulators in patients with IBS. null Methods null A 23-question survey was distributed to gastroenterologists in the United States. Comparisons in prescribing practices were conducted between (a) gastroenterologists who were "high prescribers" vers...
1 CitationsSource
#1Madusha Peiris (QMUL: Queen Mary University of London)H-Index: 12
#2Zsa Zsa R. M. Weerts (UM: Maastricht University)H-Index: 5
Last. Daniel Keszthelyi (UM: Maastricht University)H-Index: 28
view all 6 authors...
BACKGROUND Chronic and recurring pain is a characteristic symptom in irritable bowel syndrome (IBS). Altered signaling between immune cells and sensory neurons within the gut may promote generation of pain symptoms. As transient receptor potential melastatin 8 (TRPM8) agonists, such as L-menthol in peppermint oil, have shown to attenuate IBS pain symptoms, we began investigating potential molecular mechanisms. METHODS Colonic biopsy tissues were collected from patients with IBS and controls, in ...
Source
Irritable bowel syndrome (IBS) is a heterogeneous group of conditions related to specific biologic and cellular abnormalities that are not fully understood. Psychological factors do not cause IBS, but many people with IBS also have anxiety or depressed mood, a history of adverse life events, or psychosocial stressors. Physicians must understand the fears and expectations of patients and how they think about their symptoms and should also respond empathetically to psychosocial cues. Anxiety relat...
#1Shima Lorestani (MUMS: Mashhad University of Medical Sciences)H-Index: 1
#2Ali Bahari (MUMS: Mashhad University of Medical Sciences)H-Index: 13
Last. Farnaz Zahedi Avval (MUMS: Mashhad University of Medical Sciences)H-Index: 7
view all 4 authors...
Objectives null Irritable bowel syndrome (IBS) is known as one of the most common irritating gastrointestinal disorders. The mechanism behind IBS is still under investigation and it is thought that it may arose from multi factors among which free radicals have been previously mentioned. Studies have found an association between oxidative stress and IBS; however, little is known about the mechanisms and oxidative stress components status during IBS. One of the key factors playing a central role i...
Source
#1Robyn RexwinkelH-Index: 3
Last. Merit M. Tabbers (UvA: University of Amsterdam)H-Index: 29
view all 5 authors...
CONTEXT: Functional abdominal pain disorders (FAPDs) are common in childhood, impacting quality of life and school attendance. There are several compounds available for the treatment of pediatric FAPDs, but their efficacy and safety are unclear because of a lack of head-to-head randomized controlled trials (RCTs). OBJECTIVE: To systematically review the efficacy and safety of the pharmacologic treatments available for pediatric FAPDs. DATA SOURCES: Electronic databases were searched from incepti...
1 CitationsSource
#1Diego Currò (UCSC: Catholic University of the Sacred Heart)H-Index: 19
Introduction : Patients with irritable bowel syndrome (IBS) frequently resort to natural products, or request doctors to prescribe them, to relieve their symptoms, due to the poor efficacy and tolerability of several traditional drugs. Products containing fibre are among the most used and their clinical efficacy is discussed here based on the most recent scientific evidence. Areas covered : A literature search was carried out to identify the most significant publications in order to deal with th...
Source